However, a post hoc analysis of Checkmate040 with 195 HCC patients treated with nivolumab showed that patients with PD‐L1 ≥ 1% had significantly better OS than patients with PD‐L1 < 1% (28.1 months vs. 16.6 months, p = 0.032). The gene discussed is CD274; the disease is hepatocellular carcinoma.